Teprotumumab safety check in healthy chinese participants
NCT ID NCT07142642
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study tested a single dose of teprotumumab (Tepezza) in 20 healthy Chinese adults. The goal was to see how the drug moves through the body and check for side effects. Participants received either the drug or a placebo by IV, and researchers measured drug levels and any health changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teprotumumab (Tepezza)
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China